[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202101032VA - Compositions and methods for treating leber's hereditary optic neuropathy - Google Patents

Compositions and methods for treating leber's hereditary optic neuropathy

Info

Publication number
SG11202101032VA
SG11202101032VA SG11202101032VA SG11202101032VA SG11202101032VA SG 11202101032V A SG11202101032V A SG 11202101032VA SG 11202101032V A SG11202101032V A SG 11202101032VA SG 11202101032V A SG11202101032V A SG 11202101032VA SG 11202101032V A SG11202101032V A SG 11202101032VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
optic neuropathy
hereditary optic
treating leber
Prior art date
Application number
SG11202101032VA
Inventor
Bin Li
Original Assignee
Wuhan Neurophth Biotechnology Ltd Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810948193.1A external-priority patent/CN110846392A/en
Priority claimed from PCT/CN2018/103937 external-priority patent/WO2020000641A1/en
Priority claimed from CN201811221305.XA external-priority patent/CN111073899B/en
Priority claimed from CN201811230856.2A external-priority patent/CN111068071A/en
Application filed by Wuhan Neurophth Biotechnology Ltd Company filed Critical Wuhan Neurophth Biotechnology Ltd Company
Priority claimed from PCT/CN2019/101538 external-priority patent/WO2020038352A1/en
Publication of SG11202101032VA publication Critical patent/SG11202101032VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/864Parvoviral vectors, e.g. parvovirus, densovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y106/00Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/99Oxidoreductases acting on NADH or NADPH (1.6) with other acceptors (1.6.99)
    • C12Y106/99003NADH dehydrogenase (1.6.99.3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
SG11202101032VA 2018-08-20 2019-08-20 Compositions and methods for treating leber's hereditary optic neuropathy SG11202101032VA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201810948193.1A CN110846392A (en) 2018-08-20 2018-08-20 Recombinant adeno-associated virus or kit containing recombinant adeno-associated virus and application of recombinant adeno-associated virus or kit
PCT/CN2018/103937 WO2020000641A1 (en) 2018-06-29 2018-09-04 Nucleic acid for coding human nadh dehydrogenase sigmasubunit protein and application thereof
CN201811221305.XA CN111073899B (en) 2018-10-19 2018-10-19 Nucleic acid for coding human NADH dehydrogenase subunit 4 protein and application thereof
CN201811230856.2A CN111068071A (en) 2018-10-22 2018-10-22 Gene therapy for Leber genetic optic neuropathy
PCT/CN2018/113799 WO2020082417A1 (en) 2018-10-22 2018-11-02 Gene therapy for leber's hereditary optic neuropathy
PCT/CN2018/118662 WO2020077756A1 (en) 2018-10-19 2018-11-30 Coding sequence of nd4 protein and application thereof
PCT/CN2019/070461 WO2020037938A1 (en) 2018-08-20 2019-01-04 Recombinant aav (raav) or kit comprising same, and application thereof
PCT/CN2019/101538 WO2020038352A1 (en) 2018-08-20 2019-08-20 Compositions and methods for treating leber's hereditary optic neuropathy

Publications (1)

Publication Number Publication Date
SG11202101032VA true SG11202101032VA (en) 2021-02-25

Family

ID=74668040

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101032VA SG11202101032VA (en) 2018-08-20 2019-08-20 Compositions and methods for treating leber's hereditary optic neuropathy

Country Status (8)

Country Link
US (2) US11352645B2 (en)
EP (1) EP3840785A4 (en)
JP (2) JP7403852B2 (en)
KR (1) KR20210068014A (en)
CN (1) CN112584874A (en)
AU (1) AU2019323434A1 (en)
CA (1) CA3109432A1 (en)
SG (1) SG11202101032VA (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019296451B2 (en) 2018-06-29 2021-04-29 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3840785A4 (en) 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
CN113025633B (en) * 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 Nucleic acid for encoding human NADH dehydrogenase subunit 1 protein and application thereof
BR112024002305A2 (en) * 2021-08-06 2024-04-30 Wuhan Neurophth Biotechnology Ltd Company COMPOSITION AND METHOD FOR TREATMENT OF LEBER'S HEREDITARY OPTICAL NEUROPATHY CAUSED BY ND4 MUTATION
WO2024144330A1 (en) * 2022-12-29 2024-07-04 주식회사 엣진 Mitochondrial base mutation editing system for leber hereditary optic neuropathy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
CA2153391C (en) 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
AU2668897A (en) 1996-04-19 1997-11-12 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
AU2001250912B2 (en) * 2000-03-21 2007-01-04 Curagen Corporation VEGF-modulated genes and methods employing them
WO2002082904A2 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
DK3290513T3 (en) 2004-06-01 2022-12-12 Genzyme Corp COMPOSITIONS AND METHODS FOR PREVENTING AAV VECTOR AGGREGATION
US20130022979A1 (en) * 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
ES2541771T3 (en) 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression of a mitochondrial protein through an improved allotopic approach
WO2008063802A2 (en) 2006-10-23 2008-05-29 University Of Florida Research Foundation, Inc. Suppression of mitochondrial oxidative stress
US8278428B2 (en) * 2007-02-16 2012-10-02 John Guy Mitochondrial nucleic acid delivery systems
EP2162747B1 (en) * 2007-06-20 2014-04-30 Galapagos N.V. Molecular targets and methods to identify compounds for treating bone and joint degenerative diseases
AU2009308380B2 (en) * 2008-10-22 2015-05-28 Suzhou Ribo Life Science Co., Ltd. Methods for treating eye disorders
MX340102B (en) 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy.
CN102517304B (en) 2011-12-16 2013-08-28 中国农业科学院生物技术研究所 Optimized gene of recombinant glucose oxidase and expression vector and application of optimized gene
US20160289674A1 (en) * 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
CN102634527B (en) * 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 Recombinant human NADH dehydrogenase subunit 4 gene and expression vector construction method thereof
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
BR112017005524A2 (en) 2014-09-17 2018-03-06 The Univ Of Iowa Research Foundation viral RNA segments as immunomodulatory agents and vaccine components
CN104450747B (en) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 For treating the full length gene of recombinant adeno-associated virus nadh dehydrogenase subunit 4 and medicament of Leber hereditary optic neuropathies
US10450585B2 (en) 2015-07-13 2019-10-22 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CA2973885A1 (en) * 2016-07-21 2018-01-21 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial-targeted creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
CN110049769A (en) * 2016-12-04 2019-07-23 阿拉维·霍拉萨尼·默哈达姆·马塞尔·维克托 Methods of treating diseases associated with mitochondrial stress
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
WO2019033119A1 (en) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
WO2019204304A2 (en) * 2018-04-16 2019-10-24 The Children's Hospital Of Philadelphia Mitochondrial rna import for treating mitochondrial disease
CA3103231A1 (en) * 2018-06-11 2019-12-19 Serge FITOUSSI Recombinant aav vectors and methods of using the same
CN110846392A (en) 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 Recombinant adeno-associated virus or kit containing recombinant adeno-associated virus and application of recombinant adeno-associated virus or kit
CN111068071A (en) 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 Gene therapy for Leber genetic optic neuropathy
WO2020010491A1 (en) 2018-07-09 2020-01-16 武汉纽福斯生物科技有限公司 Nucleic acid for encoding human nadh dehydrogenase subunit 4 protein and application thereof
WO2020000641A1 (en) 2018-06-29 2020-01-02 武汉纽福斯生物科技有限公司 Nucleic acid for coding human nadh dehydrogenase sigmasubunit protein and application thereof
CN111073899B (en) 2018-10-19 2021-01-01 武汉纽福斯生物科技有限公司 Nucleic acid for coding human NADH dehydrogenase subunit 4 protein and application thereof
AU2019296451B2 (en) 2018-06-29 2021-04-29 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020001657A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020038352A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3840785A4 (en) 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113025633B (en) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 Nucleic acid for encoding human NADH dehydrogenase subunit 1 protein and application thereof

Also Published As

Publication number Publication date
CA3109432A1 (en) 2020-02-27
JP2021534201A (en) 2021-12-09
CN112584874A (en) 2021-03-30
JP2024028861A (en) 2024-03-05
KR20210068014A (en) 2021-06-08
US20210189429A1 (en) 2021-06-24
US11352645B2 (en) 2022-06-07
US20220259619A1 (en) 2022-08-18
EP3840785A4 (en) 2022-07-13
EP3840785A1 (en) 2021-06-30
AU2019323434A1 (en) 2021-02-25
JP7403852B2 (en) 2023-12-25

Similar Documents

Publication Publication Date Title
SG11202101032VA (en) Compositions and methods for treating leber's hereditary optic neuropathy
EP3880809A4 (en) Compositions and methods for treating wilson's disease
ZA202101362B (en) Compositions and methods for treating the eye
EP3826666A4 (en) Compositions and methods for treating nrp2-associated diseases
SG11202012044QA (en) Compositions and methods for treating leber's hereditary optic neuropathy
IL285886A (en) Compositions and methods for treating laminopathies
MA56187A (en) TREATMENTS FOR HEREDITARY ANGIOEDEMA
EP4085144A4 (en) Compositions for treating friedreich's ataxia
ZA202102302B (en) Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder
EP3927710A4 (en) Compositions and methods for treating or preventing alzheimer's disease
IL285796A (en) Methods and compositions for treating
EP3762505A4 (en) Compositions and methods for treating parkinson's disease
IL304404A (en) Compositions and methods for treating hereditary angioedema
EP3976187A4 (en) Methods and compositions for treating epilepsy
IL282150A (en) Compositions and methods for treating and preventing leber's hereditary optic neuropathy
SG11202105242TA (en) Composition for treating hair loss or promoting hair growth
ZA202101361B (en) Compositions and methods for treating the eye
GB202214988D0 (en) Compositions and methods for preventing or treating nephrolithiasis
EP3603392A4 (en) Fungicide composition for treating the banana and/or plaintain tree
SG11202109180RA (en) Compositions and methods for treating huntington's disease
EP3870210A4 (en) Compositions and methods for treating or preventing fibrosis
EP3760199A4 (en) Composition for preventing or treating hair loss
EP4058043A4 (en) Compositions and methods for treating or preventing crohn's disease
ZA202107235B (en) Compositions and methods for treating ocular disease
EP3873525A4 (en) Compositions and methods for treating brain injury